Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

NCT04842877 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT04842877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04842877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 11, 2021
Completion date
October 31, 2026
Enrollment
141 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell